OBJECTIVES:Clinical pharmacists are increasingly recognized as essential members of multidisciplinary palliative care teams, yet their specific roles and impact have not been comprehensively summarized. This scoping review aimed to systematically map and synthesize published evidence on the clinical roles, interventions, and professional contributions of pharmacists within multidisciplinary palliative care services for patients with non-communicable diseases. METHODS:A scoping review was conducted by searching PubMed, Embase, Web of Science, and Scopus from January 2000 to May 2024. Eligible studies reported clinical pharmacist interventions in palliative care. Data were extracted on study characteristics, pharmacist activities, and clinical outcomes. RESULTS:Twelve studies were included, predominantly from the United States. Pharmacist-led interventions encompassed medication reconciliation (91.7%), symptom management (83.3%), adverse drug event prevention (75.0%), patient and caregiver education (58.3%), and policy-level contributions (33.3%). High physician acceptance rates (≥90%) were consistently reported. Outcomes included improved symptom control, reduced drug-related problems, and enhanced patient-reported quality of life. SIGNIFICANCE OF RESULTS:This scoping review synthesizes current evidence on the roles of clinical pharmacists in palliative care teams. The findings highlight their essential contributions to medication safety, symptom management, deprescribing, and opioid stewardship, reinforcing the need for pharmacist integration into multidisciplinary palliative care models to improve patient-centered outcomes. Future research should focus on implementation models, cost-effectiveness analyses, and service expansion in community-based settings.

Recent advancements in tumor therapy have centered on novel treatments, particularly immune checkpoint inhibitors (ICIs), which have transformed cancer treatment since their global approval in 2011. ICIs have demonstrated remarkable and substantial efficacy across a range of malignancies, including malignant melanoma, non-small cell lung cancer (NSCLC), head and neck cancers, renal carcinoma, and selected gastrointestinal cancers. Despite these promising outcomes, the challenges that during the clinical application, such as relatively low response rates and the occurrence of immune-related adverse events, can limit therapeutic benefits. Accumulating evidence highlights the gut microbiome as a critical modulator of cancer immunotherapy efficacy. Notably, alterations in gut microbiota composition observed in response to ICI therapy, and specific bacterial populations (such as an increased Clostridiales/ Baceroidales ratio, etc.) have been associated with improved responses in patients with NSCLC and renal cell carcinoma. However, the composition and function of the gut microbiome are influenced by a variety of factors, among which concomitant drug use plays a particularly prominent role. Medications commonly prescribed to cancer patients, such as antibiotics, proton pump inhibitors (PPIs), and probiotics, can significantly alter microbial communities, potentially impacting immunotherapy outcomes. Thus, there is a compelling need for rigorous research to elucidate how such drug-induced shifts in gut microbiota affect patient responses to ICIs. Thus, we conducted a meta-analysis which included 69 studies, 102 cohorts (22,568 patients were included) to systematically investigate the influence of drug interventions, including PPIs, antibiotics and probiotics on gut microbiome dynamics and ICI effectiveness. Progression-free survival (PFS), Overall survival (OS) and Objective response rate (ORR) were utilized as the main meta notions, while a subgroup analysis was determined based on: (1) tumor type; (2) exposure time window; (3) Treatment scheme as well. The total HR and 95% CI for PFS and OS are calculated separately for each intervention (probiotics, antibiotics, and PPIs) to compare their impact on ICI immunotherapy. Our research showed that the concurrent use of antibiotics or PPIs with ICIs was associated with significantly OS, PFS, and ORR. In contrast, probiotic supplementation demonstrated promising results with improved efficacy metrics. Besides, in subgroup analysis, patients using antibiotics within three months before or after the initiation of ICI therapy, OS, PFS, and ORR were significantly lower compared to those who did not receive antibiotics; the timing of antibiotic or PPI administration consistently resulted in poorer outcomes; a negative correlation between PPI use and OS, PFS, and ORR across treatment modalities was also exhibited. By elucidating the interplay between these factors, this study aims to provide robust evidence for optimizing ICI therapy, and to enlighten cancer treatment strategies more personalized, effective and safer, ultimately advancing patient care in oncology.

Abstract Backgrounds: Since the treatment for lung cancer has been developing rapidly during the past decades, the mortality of lung cancer still remains high rate. Nutrition support plays an important role during cancer treatment. However, no standard proposal has been determined for cancer therapy. Methods: To establish a proper, strong basic knowledge for providing an appropriate nutrition support method in the treatment of lung cancer. A multi-center real world research to explore the significance of nutrition support in the process, especially enteral nutrition was conducted in this research. Results: Our research revealed that an appropriate enteral nutrition support would not only significantly reduce the incidence of adverse drug reactions (ADR) during anti-tumor therapy, but prolong the overall survival (OS), decrease mortality rates, as well as the improvement of patient prognosis. However, the occurrence of digestive system ADR might be increased, with an optimal increased levels of albumin (ALB), which can be the reason of the risk decrease of patient mortality. Conclusions: Thus, a propriate nutrition support method should be considered individually during lung cancer treatment, based on the comprehensive situation of patients and should be consistently provided. Trial Registration: This study was registered in Clinicaltrial.gov, asa the registration number is ChiCTR2300070143.

Introduction:: It is well known that the response to and metabolism of the drugs entering the human body varies widely across individuals. One of the reasons is that such interpersonal differences may be related to gut microbes. On one hand, drugs or xenobiotics entering the human body may affect the composition of the gut microbiome; on the other hand, the gut microbiota may alter the absorption, distribution, metabolism and excretion (abbreviated as ADME) process of drugs or xenobiotics vice versa. However, the majority of studies focused on the interaction of general population cohorts with the gut microbiota, which is incompatible with the real clinic. For example, the gut microbiota is closely associated with the progression and treatment of irritable bowel syndrome, a common functional disorder of the gastrointestinal tract. Under the disease status, the composition of the gut microbiota is altered affecting the pharmacokinetics, efficacy and toxicity of xenobiotics. Concerning irritable bowel syndrome, a few studies reported that the xenobiotics administration process was gut microbial-mediated, while it also affected drug efficacy and toxicity. Thus, the correlation between gut microbiota and xenobiotics administration, especially the drugs administered, should be elucidated. Method:: This review paper links differences between the gut microbiome and drug metabolism, which play a significant role in the implications for medical therapy and drug development in irritable bowel syndrome indications. Result:: The human intestinal microbiota permeates the ADME process of orally administered drugs and has the potential to further modify the efficacy and toxicity of agents through the mediation of various enzymes, while at the same time, medications could also alter the composition and function of the human intestinal microbiota.

The aim of this study was to explore effects of palliative care (PC) on patients with different heart function. Patients with NYHA (New York Heart Association) class II, III, IV were divided into separate groups. The KCCQ (Kansas City Cardiomyopathy Questionnaire) and HADS (Hospital Anxiety and Depression Scale) scores were compared before and 3 months after PC intervention. After 3 months, compared with the control group, PC could further significantly improve the KCCQ, HADS-depression and -anxiety scores of patients in NYHA class IV (P < 0.05); PC could significantly improve the HADS-depression and -anxiety scores of patients with NYHA class III (P < 0.05), and had an improvement tendency on KCCQ score. The study revealed that PC can significantly improve anxiety and depression of patients with NYHA class III or IV, and significantly improve the quality of life of patients with NYHA class IV, but had no effects on patients with NYHA class II.(c) 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

目的探讨pri-miR-378 rs1076064与肺癌铂类联合化疗毒副反应的相关性。方法本研究共纳入467名接受至少两个周期铂类化疗的肺癌患者,使用飞行时间质谱对rs1076064进行基因分型,使用无条件逻辑回归分析评估化疗后毒性反应与其基因型的相关性。结果研究发现,携带pri-miR-378 rs1076064 G等位基因的小细胞肺癌患者铂类联合化疗的总毒副反应风险增加（校正OR=2.744,95%CI=1.089～6.909,P=0.032）;在分层分析中发现,pri-miR-378 rs1076064在依托泊苷联合铂类化疗（加性模型:校正OR=2.820,95%CI=1.119～7.103,P=0.028;显性模型:校正OR=6.105,95%CI=1.108～33.650,P=0.038）、以顺铂为基础的化疗（加性模型:校正OR=1.931,95%CI=1.026～3.636,P=0.041）、男性人群（显性模型:校正OR=2.120,95%CI=1.115～4.029,P=0.022）和小细胞肺癌（加性模型:校正OR=2.637,95%CI=1.066～6.524,P=0.036;显性模型:校正OR=8.912,95%CI=1.051～75.56,P=0.045）人群中与铂类联合化疗后血液毒副反应显著相关;但未见与胃肠道毒副反应的相关性。结论 pri-miR-378 rs1076064有可能作为预测中国肺癌相关患者人群铂类化疗血液毒性的候选生物标志物。

OBJECTIVE:To study the epidemiological correlation and drug resistance of external factors of infection caused by open injury of limbs to pathogens. METHODS:This experiment is a retrospective study. We took the geographical location and climate of Nanchang, Jiangxi Province, China as the background, analyzed 2017 strains of pathogens from 1589 patients with limb trauma infection in a University Affiliated Hospital from 2012 to 2017. Patients were divided into three groups according to the type of incision: I, In-hospital infection of clean limb incision, II, In-hospital infection with open injury, III, Community infection with open injury of the limb. Groups II and Groups III were divided into six subgroups according to the causes of trauma, including: accidents from non-motor vehicles, machinery, cutting/piercing, pedestrian injuries, struck by/against, pedal cycles, and other injuries. We found eight common pathogens of orthopedic infection, which were mainly divided into Gram-positive bacteria (G+, mainly including Staphylococcus) and Gram-negative bacteria (G-, mainly Enterobacteriaceae). The relationship between main pathogens and damage mechanism, apparent temperature and relative humidity was discussed in this study. SPSS v22.0 was used for statistical analysis of the data. Friedman's two-way ANOVA was used to analyze the difference between the injury mechanism and incidence of pathogenic bacteria. Linear regression was used to determine the trend between the incidence of major pathogens and seasonal temperature and humidity. The level of significance was set as P < 0.05. RESULTS:There was no significant difference in the distribution of pathogens between Groups II and Groups III (P>0.05). The drug resistance of Groups III was significantly higher than that of Groups II and Groups I. G+ bacteria were resistant to cephalosporin, ceftriaxone and other cephalosporins and erythromycin and other macrolides. They were sensitive to vancomycin and linezolid. G- were resistant to the first- and the second-generation cephalosporins, including cefotetan and cefazolin, and ampicillin and other penicillins, while they were sensitive to third-generation cephalosporins, such as ceftazidime, as well as to levofloxacin and other quinolones, meropenem, and other beta-lactamases. The correlation between the injury mechanism and infection of pathogenic bacteria was not significant. The monthly average apparent temperature and relative humidity were correlated with the infection rate of pathogenic bacteria. CONCLUSION:In open injury of extremities, apparent temperature and relative humidity is an important risk factor for infection by pathogenic bacteria and the drug resistance of pathogenic bacteria in out-of-hospital infection was lower than that of hospital infection.

It is well known that the response to and metabolism of the drugs entering human body varies widely across individuals, one of which the reason is that such interpersonal differences may be related to gut microbes. On one hand, drugs or xenobiotics entering into human body may affect the composition of the gut microbiome; on the other hand, the gut microbiota may alter the ADME process of drugs or xenobiotics vise versa. But the majority of studies were focused on the interaction of general population cohorts with the gut microbiota, which is not compatible with the real clinic. For example, irritable bowel syndrome, a common functional disorder of the gastrointestinal tract, of which the gut microbiota is closely associated with the progression and treatment of the disease. Under the disease status, the composition of the gut microbiota is altered and affects the pharmacokinetics, efficacy and toxicity of xenobiotics. With a regard to irritable bowel syndrome, few researches reported that xenobiotics administration process was gut microbial-mediated, while effected on drug efficacy and toxicity as well. Thus, the correlation between gut microbiota and xenobiotics administration, especially the drugs administered, needs to be elucidated. This review links interpersonal differences between gut microbiome and drug metabolism, which plays a significant role in the implications for medical therapy and drug development in irritable bowel syndrome indications. Key words: gut microbiota, gut microbiota-drug interaction, xenobiotics, pharmacokinetics, probiotics

Abstract Objective: This study aimed to assess the efficacy and safety of a new hemostatic gelatin matrix for use in spinal surgery.Methods: From September to December 2020, 54 patients from our hospital were recruited and randomly allocated to a test group or a control group using computer-generated randomization codes. In the test group, the new hemostatic gelatin matrix was used; in the control group, the Surgiflo™ Hemostatic Matrix was used. All operations for both groups were performed by a senior physician, and the following measures were recorded for comparison: (i) rates of successful hemostasis at 5 min; (ii) time to hemostasis; (iii) blood pressure (BP); (iv) red blood (RBC) cell count; and (v) hemoglobin (Hb) levels in the preoperative period, 1st to 2nd postoperative days, and 42nd postoperative day. Adverse events following surgery were also compared. Results: All patients were followed up for at least 6 weeks. In the test group, 24 and 2 cases achieved and did not achieve hemostasis within 5 min, respectively. In the control group, 23 and 2 cases achieved and did not achieve hemostasis within 5 min, respectively. There was no statistical difference between the two groups (P = 0.967). The time to hemostasis, BP, RBC, and Hb in the preoperative period, on the 1st and 2nd postoperative days, and 42nd postoperative day also showed no significant differences between groups (P > 0.05).Conclusion: The new hemostatic gelatin matrix has the same efficacy and safety as that of Surgiflo™ Hemostatic Matrix.

Objective: Curcumin has good anti-inflammatory and antioxidant properties, and whether it can resist osteoporosis through oxidative stress pathway in a dose-dependent manner. Method: we used an oxidative stress cell model by culture cells with hydrogen peroxide (H 2 O 2 ), cells were osteogenic differentiation after treated with H 2 O 2 ，different concentration curcumin were added during differentiation, then measured the early and late osteogenic index, and detected the potential signaling pathway involved. In addition, we employed rat OVX model treated with curcumin to confirm the protection of the anti-oxidant. Result: Low concentrations of curcumin (1-10μM) promoted the proliferation of MC3T3-E1 cells, improved alkaline phosphatase (ALP) activity, elevated calcium content against oxidative stress induced by H2O2, but high concentration (20 μM) failed, moreover, curcumin diminished supernatant receptor activator of nuclear factor kappa-B ligand (RANKL) and IL-6 expression, inhibited the intracellular ROS triggered by H2O2, Notably, curcumin exerted protection by blocking the NF-κB signaling pathway. The curcumin administered for 12 weeks partially reversed the raito of blood malondialdehyde (MDA) and glutathione (GSH) activity in ovariectomized (OVX) rat in vivo. It also increased the bone mineral density (BMD) and improved the micro-architecture of trabecular bones. Conclusion: curcumin exerted protection on osteoporosis, the effect linked to a reduction of oxidative stress and bone resorbing cytokine, This study suggests that curcumin might be a candidate for osteoporosis prevention and the low concentration exerted obviously protection.

INTRODUCTION:Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swept rapidly throughout the world. So far, no therapeutics have yet proven to be effective. Ribavirin was recommended for the treatment of COVID-19 in China because of its in vitro activity. However, evidence supporting its clinical use with good efficacy is still lacking. METHODS:A total of 208 confirmed severe COVID-19 patients who were hospitalized in Wuhan Union West Campus between 1 February 2020 and 10 March 2020 were enrolled in the retrospective study. Patients were divided into two groups based on the use of ribavirin. The primary endpoint was the time to clinical improvement. The secondary endpoints included mortality, survival time, time to throat swab SARS-CoV-2 nucleic acid negative conversion, and the length of hospital stay. RESULTS:68 patients were treated with ribavirin while 140 not. There were no significant between-group differences in demographic characteristics, baseline laboratory test results, treatment, and distribution of ordinal scale scores at enrollment, except for coexisting diseases especially cancer (ribavirin group vs no ribavirin group, P = 0.01). Treatment with ribavirin was not associated with a difference in the time to clinical improvement (P = 0.48, HR = 0.88, 95% CI = 0.63-1.25). There were also no significant differences between-group in SARS-CoV-2 nucleic acid negative conversion, mortality, survival time, and the length of hospital stay. CONCLUSIONS:In hospitalized adult patients with severe COVID-19, no significant benefit was observed with ribavirin treatment.

Bone-destructive diseases, caused by overdifferentiation of osteoclasts, reduce bone mass and quality, and disrupt bone microstructure, thereby causes osteoporosis, Paget's disease, osteolytic bone metastases, and rheumatoid arthritis. Osteoclasts, the only multinucleated cells with bone resorption function, are derived from haematopoietic progenitors of the monocyte/macrophage lineage. The regulation of osteoclast differentiation is considered an effective target for the treatment of bone-destructive diseases. Natural plant-derived products have received increasing attention in recent years due to their good safety profile, the preference of natural compounds over synthetic drugs, and their potential therapeutic and preventive activity against osteoclast-mediated bone-destructive diseases. In this study, we reviewed the research progress of the potential antiosteoclast active compounds extracted from medicinal plants and their molecular mechanisms. Active compounds from natural plants that inhibit osteoclast differentiation and functions include flavonoids, terpenoids, quinones, glucosides, polyphenols, alkaloids, coumarins, lignans, and limonoids. They inhibit bone destruction by downregulating the expression of osteoclast-specific marker genes (CTSK, MMP-9, TRAP, OSCAR, DC-STAMP, V-ATPase d2, and integrin av3) and transcription factors (c-Fos, NFATc1, and c-Src), prevent the effects of local factors (ROS, LPS, and NO), and suppress the activation of various signalling pathways (MAPK, NF-κB, Akt, and Ca2+). Therefore, osteoclast-targeting natural products are of great value in the prevention and treatment of bone destructive diseases.

Background The tumor microenvironment plays an important role in the progression and malignancy of lung adenocarcinoma and affects the immunotherapy response. There is increasing evidence that long non-coding RNAs (lncRNAs) as competing endogenous RNAs (ceRNAs) have significant functions in the development and treatment response of various kinds of cancer. This study aimed to explore the association between immune-related lncRNA-microRNA (miRNA)-messenger RNA (mRNA)-ceRNA networks, and the prognosis of and immunotherapy response in lung adenocarcinoma. Methods RNA-sequencing (RNA-seq) and miRNA-seq data from The Cancer Genome Atlas (TCGA) were used to evaluate the infiltration of immune cells in lung adenocarcinoma samples by undertaking a single-sample gene set enrichment analysis (ssGSEA) to divide the cells into high and low immune cell infiltration groups. The differentially expressed mRNA (DEmRNA) was further analyzed by a weighted gene co-expression network analysis (WGCNA), search tool for recurring instances of neighboring genes (STRING), and Cytoscape to select hub genes. The ceRNA network was constructed using Cytoscape. Additionally, survival analyses were conducted to screen out prognostic candidate genes. Results Seven thousand five hundred and thirty-eight mRNAs, 540 lncRNAs, and 138 miRNAs were found to be differentially expressed between the high and low immune cell infiltration groups. The two DEmRNA modules most significantly associated with immune cell infiltration were further analyzed, and four clusters, including 179 DEmRNAs, were selected based on Molecular Complex Detection (MCODE) scores. The selected DEmRNAs in the four clusters were mainly enriched in pathways involved in regulating the immune response. Ultimately, a ceRNA network of SNHG6-hsa-miR-30e-5p-CYSLTR1 was identified as being associated with the prognosis of and immunotherapy response in lung adenocarcinoma. Conclusions The present study extends understandings of immune-related lncRNA-miRNA-mRNA-ceRNA networks and identifies novel targets and a regulatory pathway for anti-tumor immunotherapy.

目的:探讨振荡溶解速率对注射用重组人促红素溶解后体内外活性的影响,为临床应用提供参考。方法:参照中国药典2015年版三部,按酶联免疫法试剂盒说明书测定高、中、低(800,1 600 2 300 min -1 )不同振荡速率下注射用重组人促红素及对照药品重组人促红素注射液B和C体外活性;参照通则3522方法,采用近交系6～8周龄雌性BALB/C小鼠测定不同振荡速率注射用重组人促红素及注射液的体内活性;采用单因素方差分析或非参数检验对各组体内外活性结果进行比较。结果:注射用重组人促红素在低速振荡频率时的体内外活性均显著低于其他各组（P＜0.01）;中、高速振荡速率组与注射液B和C组的体外活性相当但体内活性仍存在显著差异（P＜0.01）。结论:临床配置注射用重组人促红素时应尽量采用中、高速的振荡频率,以尽可能获得更佳的体内生物学活性。

新型冠状病毒感染肺炎重症患者的营养不良状态会对其疾病预后产生重要影响。根据相关指南及共识,提出新型冠状病毒感染肺炎重症患者的营养支持及监护建议。

Objective:To establish a predictive equation for the osmolarity of parenteral nutritional prescription in China.Methods:From July 2019 to September 2019, 2 480 individualized samples of 328 different parenteral nutritional prescriptions (adult) of Peking Union Medical College Hospital were collected, and the osmolarity of parenteral nutritional solution samples was determined by a freezing point reduction method. Pearson χ2 test and a multiple linear regression analysis were utilized to establish a prediction equation for the osmolality of parenteral nutritional solution. Results:The average osmolarity of parenteral nutritional prescription was (1 164.20 ± 252.59) mOsm/kg, and the best fitting equation was (9.66A+ 7.88G+ 3.52F+ 36.4Na+ 27.55K+ 3.38P+ 7.46W-250)/V.Conclusion:The osmolarity is determined accurately and effectively by the fitting equation, which provide a benefit reference for the formulation, review and selection of clinical parenteral nutrition prescription especially in China.

目的:探索新型冠状病毒肺炎疫情下方舱医院药学服务新模式方法:满足方舱医院患者药学服务需求,开展以微信等形式为主的线上药学服务模式。结果与结论:通过开展以微信为主要方式的线上药学服务模式,不仅能够有效减少医院获得性感染机会,还能提高药学服务效率,实现患者全程及时有效的得到专业用药指导。

Background: Coronavirus disease-2019 (COVID-19) spreads rapidly throughout the world. So far, no therapeutics have yet been proven to be effective. Ribavirin was recommended for the treatment of COVID-19 because of its in vitro activity. However, evidence supporting its clinical use with good efficacy is still lacking. Methods: A total of 208 confirmed severe or critical COVID-19 patients who were hospitalized in Wuhan Union West Campus between 1 February 2020 and 10 March 2020 were enrolled in the retrospective study. Patients were divided into two groups based on the use of ribavirin. The primary endpoint was the time to clinical improvement. The secondary endpoints included mortality, survival time, time to throat swab SARS-CoV-2 nucleic acid negative conversion, and hospital duration. Results: 68 patients were treated with ribavirin while 140 not. There were no significant between-group differences in demographic characteristics, baseline laboratory test results, treatment, and distribution of ordinal scale scores at enrollment, except coexisting diseases especially cancer (ribavirin group vs no ribavirin group, P = 0.014). Treatment with ribavirin was not associated with a difference in the time to clinical improvement ( P = 0.483, HR = 0.884, 95% CI = 0.627-1.247). There were also no significant differences between-group in the number of patients with SARS-CoV-2 nucleic acid negative conversion, mortality, survival time, and hospital duration. Conclusion: In hospitalized adult patients with severe or critical COVID-19, no significant benefit was observed with ribavirin treatment.

Signal transducer and activator of transcription (STAT) 3 plays a vital role in carcinogenesis and drug response. Platinum-based chemotherapy is the first-line treatment for lung cancer patients, especially those in advanced stages. In the present study, we investigated the association of STAT3 polymorphism rs4796793 with lung cancer susceptibility, platinum-based chemotherapy response, and toxicity.

目的 了解伏立康唑致肝毒性的临床特点、治疗与转归.方法 检索国内外数据库中伏立康唑致肝毒性的报道,比较伏立康唑治疗前后相关检测指标,分析伏立康唑致肝毒性的临床特点和预后.采用药物性肝损伤因果关系评价法(RUCAM评分量表对伏立康唑与肝毒性关联性进行评价.结果 共纳入文献病例16例,其中男13例,女3例;平均55岁,50%患者年龄>65岁;单独使用伏立康唑3例,伏立康唑合并使用质子泵抑制药6例;14例患者肝毒性发生在应用伏立康唑后20 d内;伏立康唑肝毒性主要临床表现为全身不适、乏力、恶心、呕吐、四肢肌肉酸痛、皮肤黄染等;实验室检查主要表现为转氨酶升高.发生肝毒性后,2例患者减量继续用药,其余14例患者停药或换药治疗;13例病情缓解;11例患者于停药20 d内症状消失.RUCAM量表关联性分析结果显示,16例患者肝毒性均与伏立康唑相关.结论 伏立康唑致肝毒性的发生涉及患者年龄、性别、原患疾病、药物相互作用等多种因素,临床应用时需加强监测,以减少不良反应.